Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma 3Hodgkin Disease 3Glioblastoma 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Gliosarcoma 2Central Nervous System Neoplasms 2Burkitt Lymphoma 2Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Leukemia, Large Granular Lymphocytic 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Enteropathy-Associated T-Cell Lymphoma 1Breast Neoplasms 1

Interventions

Doxorubicin 2tazemetostat 1romidepsin 1pembrolizumab 1etoposide phosphate 1duvelisib 1cc-486 1Vincristine 1Prednisone 1Prednisolone 1Melphalan 1Etoposide 1Cytarabine 1Cyclophosphamide 1Carmustine 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Enteropathy-Associated T-Cell Lymphoma × Carmustine × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡